You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

Claims for Patent: 8,785,491

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,785,491

Title:	Pharmaceutical compositions and methods for treating age-related macular degeneration with melatonin analogues
Abstract:	Pharmaceutical compositions and methods for treating and/or preventing age-related macular degeneration with melatonin analogues are provided.
Inventor(s):	Baron; David (Skokie, IL), Hirai; Keisuke (Osaka, JP), Shintani; Yasushi (Osaka, JP), Uchikawa; Osamu (Osaka, JP)
Assignee:	Takeda Pharmaceuticals U.S.A., Inc. (Deerfield, IL)
Application Number:	13/063,672
Patent Claims:	1. A method for treating age-related macular degeneration in a patient in need thereof, wherein said method comprises identifying a patient in need of treatment for age-related macular degeneration, and administering (S)--N-[2-[4-hydroxy-1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl]ethyl]- propionamide to said patient. 2. The method of claim 1, wherein the patient is identified by visual examination of the patient. 3. The method of claim 1, wherein said age-related macular degeneration is the dry form. 4. The method of claim 1, wherein said age-related macular degeneration is the wet form. 5. The method of claim 1, wherein said age-related macular degeneration occurs in one eye. 6. The method of claim 1, wherein said age-related macular degeneration occurs in two eyes. 7. The method of claim 1, wherein said administration of (S)--N-[2-[4-hydroxy-1,6,7,8-tetrahydro-2H-indeno [5,4-b]furan-8-yl]ethyl]propionamide is by an oral dosage form. 8. The method of claim 1, wherein said administration of (S)--N-[2-[4-hydroxy-1,6,7,8-tetrahydro-2H-indeno [5,4-b]furan-8-yl]ethyl]propionamide is by an injectable dosage form. 9. The method of claim 1, wherein said administration of (S)--N-[2-[4-hydroxy-1,6,7,8-tetrahydro-2H-indeno [5,4-b]furan-8-yl]ethyl]propionamide is by a skin-patch dosage form. 10. The method of claim 1, wherein said administration of (S)--N-[2-[4-hydroxy-1,6,7,8-tetrahydro-2H-indeno [5,4-b]furan-8-yl]ethyl]propionamide is by a liquid, powder, ointment, paste, gel or cream dosage form. 11. The method of claim 1, wherein said (S)--N-[2-[4-hydroxy-1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl]ethyl]- propionamide is administered in a dose of from 1 mg to 1000 mg. 12. The method of claim 1, wherein said (S)--N-[2-[4-hydroxy-1,6,7,8-tetrahydro-2H-indeno [5,4-b]furan-8-yl]ethyl]propionamide, is administered in a dose of from 1 mg to 1000 mg. 13. The method of claim 1, wherein said (S)--N-[2-[4-hydroxy-1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl]ethyl]- propionamide is administered in a dose once daily. 14. The method of claim 13, wherein said (S)--N-[2-[4-hydroxy-1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl]ethyl]- propionamide is administered in the evening. 15. The method of claim 13, wherein said (S)--N-[2-[4-hydroxy-1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl]ethyl]- propionamide is administered prior to sleep. 16. The method of claim 1, wherein said (S)--N-[2-[4-hydroxy-1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl]ethyl]- propionamide is administered in a dose twice daily. 17. The method of claim 1, wherein said (S)--N-[2-[4-hydroxy-1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl]ethyl]- propionamide is administered in a dose more than twice daily. 18. The method of claim 1, further comprising administering photodynamic therapy. 19. The method of claim 1, further comprising administering therapeutic amount of a pharmaceutical agent selected from the group consisting of bevacizumab, ranibizumab, melatonin, pegatanib, and combinations thereof. 20. A method for treating age-related macular degeneration in a patient in need thereof, wherein said method comprises administering (S)--N-[2-[4-hydroxy-1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl]ethyl]- propionamide to said patient. 21. The method of claim 20, wherein said (S)N-[2-[4 hydroxy-1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl]ethyl]propionamide administered in a dose of from 1 mg to 1000 mg. 22. The method of claim 20 further comprising administering photodynamic therapy. 23. The method of claim 20, further comprising administering therapeutic amount of a pharmaceutical agent selected from the group consisting of bevacizumab, ranibizumab, melatonin, pegatanib, and combinations thereof.

Details for Patent 8,785,491

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004	⤷ Try a Trial	2028-06-19
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	06/30/2006	⤷ Try a Trial	2028-06-19
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	08/10/2012	⤷ Try a Trial	2028-06-19
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	10/13/2016	⤷ Try a Trial	2028-06-19
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	03/20/2018	⤷ Try a Trial	2028-06-19
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.